Combination ovarian test boosts response to therapy
This article was originally published in Clinica
Executive Summary
By combining the actions of two assays, a team at Yale School of Medicine in Connecticut says it could double the response rate of ovarian cancer patients to drug therapy. The exclusive licensee of the new combination assay, Precision Therapeutics, told Clinica that a product could be available by 2007, following the completion of a prospective clinical trial scheduled to begin later this year.